152239-46-8
152239-46-8
Chemical Structure
SB 204741
- CAS No.: 152239-46-8
- Formula:C14H14N4OS
- Molecular Weight:286.35
IUPAC Name: 1-(1-methyl-1H-indol-5-yl)-3-(3-methylisothiazol-5-yl)urea
InChIKey: USFUFHFQWXDVMH-UHFFFAOYSA-N
SMILES: O=C(NC1=CC(C)=NS1)NC2=CC3=C(N(C)C=C3)C=C2
Biological Activity: SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SB 204741 | 99.85% | SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB 204741 (Standard) | ≥98% | SB 204741 (Standard) is the analytical standard of SB 204741. This product is intended for research and analytical applications. SB 204741 is a selective and high affinity 5-HT2B antagonist with a pKi value of 7.1. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-200646A | 99.14% | SB-200646A is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646A is orally active and has electrophysiological and anxiolytic properties in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-200646 | 98.38% | SB-200646 is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646 is orally active and has electrophysiological and anxiolytic properties in vivo. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
M199 | 98.55% | M199 is a potent TLR3/TLR9 signaling inhibitor. M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs. M199 is used as a selective inducer of the immune response. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
FzM1.8 | 98.93% | FzM1.8 is a Wnt/β-catenin signaling pathway agonist and an allosteric agonist of Frizzled 4 (FZD4), with a pEC50 of 6.4 for FZD4. FzM1.8 stabilizes a conformation with increased affinity for heterotrimeric G proteins, promoting Gβγ release and subsequent PI3K activation. FzM1.8 activates the AKT pathway downstream of FZD4. FzM1.8 does not affect FZD4 maturation or plasma membrane localization and does not induce FZD4 endocytosis. FzM1.8 upregulates the WNT-responsive genes C-myc and Cyclin D1, while leaving lgr5 expression unchanged. FzM1.8 can be used for colon cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BTdCPU | 99.03% | BTdCPU is a potent heme regulated inhibitor kinase (HRI) activator that promotes eIF2α phosphorylation and induces apoptosis in Dexamethasone (HY-14648) (Dex)-resistant cancer cells. BTdCPU can be used in the study of cancers such as multiple myeloma and Dex-resistant multiple myeloma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BLT-4 | 98.09% | BLT-4 is a specific, reversible inhibitor of scavenger receptor, class B, type I (SR-BI). BLT-4 inhibits the transfer of lipids between high-density lipoproteins (HDL) and cells mediated by SR-BI. . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RF03176 | RF03176 is an aquaporin-9 (AQP-9) inhibitor, also exhibiting moderate inhibition effects on mAQP3 and mAQP7. RF03176 shows no activity against mAQP8. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
p38 Kinase inhibitor 4 | p38 Kinase inhibitor 4 (compound 135) is a potent p38 inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
STING-IN-7 | 98.29% | STING-IN-7 is a potent STING inhibitor with an IC50 of 11.5 nM. STING-IN-7 can inhibit the phosphorylation of STING, IRF3, and TBK1. STING-IN-7 can be used in the research of autoimmune and inflammatory diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AK963/40708899 | AK963/40708899 is a potent PAK1 inhibitor. AK963/40708899 suppresses the proliferation of human gastric cancer cells by downregulation of PAK1-NF-κB-cyclinB1 pathway. AK963/40708899 induces cell cycle arrest at G2 phase and reduces the migration and invasion. AK963/40708899 inhibits the formation of filopodia and promots cell adhesion which in turn inhibits invasive potential of gastric cells by negatively regulating PAK1-LIMKl-cofilin and PAK1-ERK-FAK pathways. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
